PRODUCT** | Indication | Pre-clinical | Phase i/ii | Phase iii | Marketed | |
---|---|---|---|---|---|---|
Donnatal® | IBS and acute enterocolitis*** | U.S. CO-PROMOTION |
||||
EnteraGam® | Chronic diarrhea and loose stools**** | U.S. EXCLUSIVE LICENSE |
||||
Esomeprazole Strontium DR Capsules | GERD and other GI conditions***** | U.S. COMMERCIALIZATION LICENSE |
||||
TALICIA® (RHB-105) | H. pylori infections | |||||
RHB-104 | Crohn's disease | |||||
NTM infections | ||||||
BEKINDA® (RHB-102) |
Gastroenteritis & gastritis | |||||
IBS-D | ||||||
RHB-106 | Bowel cleanser | ![]() |
||||
YELIVA® (ABC294640) | Multiple indications | |||||
RHB-107 MESUPRON | Pancreatic Cancer |
RedHill Biopharma (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer.